Cargando…
P2Y(12) Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model
Current guidelines recommend initiation of a P2Y(12) inhibitor for all patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) at the time of diagnosis (pre-treatment); however, there are no randomized trials directly comparing pre-treatment with initiation at the time of angiography to su...
Autores principales: | Gunton, James, Hartshorne, Trent, Langrish, Jeremy, Chuang, Anthony, Chew, Derek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999792/ https://www.ncbi.nlm.nih.gov/pubmed/27548237 http://dx.doi.org/10.3390/jcm5080072 |
Ejemplares similares
-
Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors
por: Blanchart, Katrien, et al.
Publicado: (2021) -
ST Segment Elevation with Normal Coronaries
por: Sethi, Pooja, et al.
Publicado: (2016) -
P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis
por: Yan, Longhui, et al.
Publicado: (2022) -
Angiography-derived index of microcirculatory resistance as a novel, pressure-wire-free tool to assess coronary microcirculation in ST elevation myocardial infarction
por: De Maria, Giovanni Luigi, et al.
Publicado: (2020) -
Management of Multivessel Coronary Disease in ST-segment Elevation Myocardial Infarction
por: Banning, Amerjeet S., et al.
Publicado: (2015)